Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.
Also called NCT04218552
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 176 participants
- Sponsor
- Registry
-
NCT04218552
-
- Other papers using this trial's data
- Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04218552. Randomized; double masking; primary purpose treatment. Start 2020-02-25 (actual); primary completion 2021-02-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
- Condition
- Hypertension,Essential
- Intervention (Drug)
- AD209
- Intervention (Drug)
- Amlodipine low
- Intervention (Drug)
- Amlodipine high
- Intervention (Drug)
- Telmisartan
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct04218552- Content hash
ec0102dea9f9ac4745f90d400156bfade1722e3039ee21275fe980b82821c2bb